Pfizer Ltd. Share Price

Pfizer joins hands with Mylan to expand Ativan and Pacitane reach in India

Pfizer Ltd has signed a five-year marketing and supply agreement with Mylan Pharmaceuticals to boost the distribution of its well-known brands, Ativan and Pacitane, in India. Ativan is widely used for anxiety disorders, while Pacitane is prescribed for Parkinson’s disease and neurological conditions. Mylan, with its strong presence in the central nervous system therapy segment, will leverage its network and specialist engagement to expand the reach of these products. This collaboration aims to enhance Pfizer’s in-clinic presence by tapping into Mylan’s expertise in working with neurologists and psychiatrists. While financial details remain undisclosed, both companies have finalized commercial arrangements. The agreement is exclusive to the Indian market and does not involve any joint venture or share exchange.

Stay tuned for more such posts, Thank You!

See More

Pfizer: Why the Cipla partnership matters

# Pfizer: Why the Cipla partnership matters Pfizer Limited has partnered with Cipla to expand the reach of four established brands in India. The deal shows how Pfizer is using a stronger distribution network while retaining manufacturing and supply responsibilities. Under the agreement, Cipla gets exclusive marketing and distribution rights for Corex Dx, Corex LS, Dolonex and Neksium in India. Pfizer continues to manufacture, source and supply the medicines. This is an interesting business-model change. Pfizer already has more than 150 products across 16 therapeutic areas in India, with annual sales of over ₹2,000 crore. Its portfolio includes established brands such as Prevenar 13, Corex, Dolonex, Becosules and Folvite. The partnership allows Pfizer to use Cipla's distribution reach without transferring the manufacturing and supply side of the business. For an established-brand portfolio, distribution reach can be important because wider availability can directly influence prescription and retail sales. Pfizer has also been making organisational changes across its business, including a new leadership structure for vaccines and other therapy areas. **My view:** The Cipla partnership is more interesting as a strategy change than as a one-time corporate announcement. The key question is whether better distribution can revive growth from established brands while Pfizer continues building its higher-value portfolio I would watch sales growth of the partnered brands, Pfizer's product mix and whether similar partnerships are used for other mature brands. **What I'm watching:** revenue growth, established-brand performance, product mix, new partnerships and margins. **Stance:** The partnership should be judged by the incremental sales and profitability it creates, rather than simply the size of the brand portfolio covered. **Disclosure:** I am a SEBI Registered Research Analyst. Please refer to the applicable disclosures before taking any investment decision.

See More

Novartis India Bids Rs 1,250 Cr for Pfizer's Minipress

Novartis India has placed a ₹1,250 crore bid to acquire

's Minipress brand, an established prescription drug. 1. A brand acquisition transfers ownership of a specific product, not an entire business. Pfizer retains everything else in its portfolio, its other drugs, its manufacturing facilities, its broader operations, only the rights to Minipress specifically change hands here. 2. This is a common strategy for pharmaceutical companies managing large, diverse drug portfolios. A company like Pfizer may choose to divest individual, established brands that no longer fit its strategic focus, sometimes older, off-patent drugs with steady but unexciting growth, while a buyer like Novartis India sees an opportunity to add proven, already-marketed revenue to its own portfolio without the years of R&D and trial costs a new drug would require. 3. The price paid reflects the brand's existing customer base, prescriber relationships, and revenue history, not future R&D potential. Unlike investing in a new drug candidate, which carries significant clinical trial and approval risk, acquiring an established brand like Minipress is a bet on continuing existing, already-proven revenue streams. The takeaway: Not every acquisition is about buying a company or even a subsidiary. Pharmaceutical companies frequently trade individual, established drug brands between each other, a distinct category of deal worth recognizing separately from stake sales, mergers, or new product launches, since it reflects portfolio reshuffling around already-proven products rather than new growth bets.

See More

Novartis India Shares End 9-Day Rally, Slip Over 1%

Shares of Novartis India snapped a nine-day winning streak on Friday, declining more than 1% as investors booked profits after a sharp recent run-up. The stock was trading around Rs 2,400 on the National Stock Exchange by early afternoon, down 1.16%. Earlier in the session it had climbed as high as Rs 2,550, a gain of about 5%. The correction comes after an impressive rally that began on August 31. Over those nine sessions the stock surged 52%, driven largely by positive news related to a major trademark acquisition. On September 7 the company informed exchanges that its board had approved the purchase of the “Minipress” and “Minipres” trademarks, along with related intellectual property rights in India, from

er Inc. and Pfizer Products Inc. for a total consideration of Rs 1,250 crore. Following board approval, Novartis India signed an asset purchase agreement and trademark assignment deeds with the Pfizer entities. The deal sparked strong buying interest and propelled the stock higher in subsequent sessions.

See More

NOVARTIND Surges on Pfizer Deal; Pfizer Hits 52-Week Low

Novartis India gained sharply after acquiring Minipress from Pfizer for ₹1,250 crore, while Pfizer extended its losing streak and hit a 52-week low. Novartis India Ltd. (NSE: NOVARTIND) is in focus after acquiring the Minipress and Minipres trademarks in India, along with related intellectual property rights, from Pfizer Inc. and Pfizer Products Inc. for ₹1,250 crore. The company's Board approved the transaction on September 7, 2026, followed by the execution of an asset purchase agreement and trademark assignment deeds with Pfizer. Following the announcement, Novartis India shares gained around 48% over the past three trading sessions and ended Thursday 11% higher at ₹2,425.20. On an intraday basis, the stock's three-session rally reached 57.89%. In contrast, Pfizer Ltd. (NSE:

) remained under pressure. The stock declined around 11% over the past three trading sessions, falling 1.81% on Thursday and extending its losing streak to six consecutive sessions. During the session, Pfizer touched a fresh 52-week low of ₹4,080. According to IQVIA MAT July 2026 data, Minipress XL generated revenue of ₹228.6 crore and recorded a four-year CAGR of 6.3%, compared with 9% growth for its category. Minipress XL, containing prazosin, is prescribed for the treatment of hypertension and urinary symptoms associated with benign prostatic hyperplasia (BPH). The acquisition adds an established cardiovascular brand to Novartis India's portfolio, strengthening its presence in the domestic pharmaceutical market. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.

See More

Novartis India to acquire Pfizer's ‘Minipress’

Novartis India to acquire Pfizer's ‘Minipress’

SEBI RA – Shubh Consultancy – Sunil Kotak – INH000015826 Novartis India Ltd on Monday announced that its Board of Directors has approved the acquisition of the trademarks 'Minipress' and 'Minipres' from Pfizer Inc. USA and Pfizer Products Inc. USA for a total consideration of approximately Rs 1,250 crore. In a regulatory filing, the company said the transaction involves the acquisition of the trademarks registered in India and certain related intellectual property rights for a total aggregate consideration of Rs 1,250 crore. The company has executed an asset purchase agreement and trademark assignment deeds with Pfizer Inc USA and Pfizer Products Inc USA, with the signing and closing of the transaction scheduled to occur simultaneously, as per the filing. The company noted that Minipress XL (containing prazosin) is primarily indicated in India for treating hypertension (high blood pressure) and managing the urinary symptoms of benign prostatic hyperplasia (BPH). The filing further highlighted that as per IQVIA MAT July 2026 data, Minipress XL recorded revenue of Rs 228.6 crore and has been growing at a compound annual growth rate (CAGR) of 6.3 per cent for the past four years. In a separate filing, Pfizer Ltd said it will discontinue the marketing, distribution and sale of Minipress XL with effect from Monday. "This is consequent to a decision by Pfizer Inc USA to discontinue the manufacture of Minipress XL," it said. All this is for information This is not a buy/sell recommendation. Thank you, Technofunda24

See More